Oral Versus Intravenous Chemotherapy in COVID-19 Epidemic

Bicheng Wang, Boya Xiao
{"title":"Oral Versus Intravenous Chemotherapy in COVID-19 Epidemic","authors":"Bicheng Wang, Boya Xiao","doi":"10.54457/dr.202201001","DOIUrl":null,"url":null,"abstract":"The novel coronavirus has a significant impact on the routine clinical practice for cancer patients in China since December 2019. During the epidemic in mainland China, especially Wuhan, the intravenous chemotherapies of cancer patients were considerably delayed. Up to now, cancer patients throughout the world directly encounter similar obstacles. For patients who have the right to choose chemotherapeutic regimens with different administration routes, oral drugs can be considered to be applied. In this mini-review, oral chemotherapeutic drugs were compared with intravenous drugs in seven types of tumors. Accordingly, we intended to provide useful suggestions for clinicians to balance the benefits and risks of oral against intravenous chemotherapies and to choose properly substituted oral chemotherapeutic regimens for cancer patients amid the coronavirus disease 2019 (COVID-19) pandemic.","PeriodicalId":93445,"journal":{"name":"Infectious diseases research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.54457/dr.202201001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The novel coronavirus has a significant impact on the routine clinical practice for cancer patients in China since December 2019. During the epidemic in mainland China, especially Wuhan, the intravenous chemotherapies of cancer patients were considerably delayed. Up to now, cancer patients throughout the world directly encounter similar obstacles. For patients who have the right to choose chemotherapeutic regimens with different administration routes, oral drugs can be considered to be applied. In this mini-review, oral chemotherapeutic drugs were compared with intravenous drugs in seven types of tumors. Accordingly, we intended to provide useful suggestions for clinicians to balance the benefits and risks of oral against intravenous chemotherapies and to choose properly substituted oral chemotherapeutic regimens for cancer patients amid the coronavirus disease 2019 (COVID-19) pandemic.
2019冠状病毒病流行中的口服与静脉化疗
自2019年12月以来,新型冠状病毒对中国癌症患者的常规临床实践产生了重大影响。在中国大陆特别是武汉疫情期间,癌症患者的静脉化疗被大大推迟。到目前为止,全世界的癌症患者都直接遇到了类似的障碍。对于有权选择不同给药途径的化疗方案的患者,可以考虑采用口服药物。在这个小型回顾,口服化疗药物与静脉注射药物在7种类型的肿瘤进行比较。因此,我们旨在为临床医生提供有用的建议,以平衡口服化疗与静脉化疗的益处和风险,并在2019年冠状病毒病(COVID-19)大流行期间为癌症患者选择合适的替代口服化疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信